A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Buch/Monographie |
| Sprache: | Englisch |
| Veröffentlicht: |
London; Berlin; Heidelberg
BioMed Central; Springer
2016
|
| DOI: | 10.1186/s12885-016-2449-0 |
| Online-Zugang: | Resolving-System, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12885-016-2449-0 Resolving-System, kostenfrei, Volltext: http://nbn-resolving.de/urn:nbn:de:bsz:16-heidok-214656 
|
| Verfasserangaben: | N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G.M. Haag, M. Rieger, O.G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran |
MARC
| LEADER | 00000cam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1658578104 | ||
| 003 | DE-627 | ||
| 005 | 20230427061920.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 160830s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a urn:nbn:de:bsz:16-heidok-214656 |2 urn | |
| 024 | 7 | |a 10.1186/s12885-016-2449-0 |2 doi | |
| 035 | |a (DE-627)1658578104 | ||
| 035 | |a (DE-576)476635187 | ||
| 035 | |a (DE-599)BSZ476635187 | ||
| 035 | |a (OCoLC)958044234 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hänse, Nicole |d 1990- |e VerfasserIn |0 (DE-588)1112570209 |0 (DE-627)866553517 |0 (DE-576)47663685X |4 aut | |
| 245 | 1 | 2 | |a A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors |c N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G.M. Haag, M. Rieger, O.G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran |
| 264 | 1 | |a London; Berlin; Heidelberg |b BioMed Central; Springer |c 2016 | |
| 300 | |a 1 Online-Ressource (10 Seiten) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Aus: BMC Cancer, 16 (2016), Nr. 420. pp. 1-10. ISSN 1471-2407 | ||
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-016-2449-0 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://nbn-resolving.de/urn:nbn:de:bsz:16-heidok-214656 |q application/pdf |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a BO | ||
| 992 | |a 20160830 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |e 910000PM132561972 |e 910400PM132561972 |k 0/910000/ |k 1/910000/910400/ |p 5 | ||
| 999 | |a KXP-PPN1658578104 |e 3403226239 | ||
| BIB | |a Y | ||
| JSO | |a {"note":["Aus: BMC Cancer, 16 (2016), Nr. 420. pp. 1-10. ISSN 1471-2407"],"physDesc":[{"extent":"1 Online-Ressource (10 Seiten)"}],"type":{"media":"Online-Ressource","bibl":"book"},"id":{"doi":["10.1186/s12885-016-2449-0"],"uri":["urn:nbn:de:bsz:16-heidok-214656"],"eki":["1658578104"]},"language":["eng"],"title":[{"title":"A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors","title_sort":"phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors"}],"person":[{"role":"aut","display":"Hänse, Nicole","given":"Nicole","family":"Hänse"},{"role":"aut","family":"Marmé","display":"Marmé, Frederik","given":"Frederik"}],"recId":"1658578104","origin":[{"dateIssuedKey":"2016","publisherPlace":"London; Berlin; Heidelberg","publisher":"BioMed Central; Springer","dateIssuedDisp":"2016"}],"name":{"displayForm":["N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G.M. Haag, M. Rieger, O.G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran"]}} | ||
| SRT | |a HAENSENICOPHASEITRIA2016 | ||